USPTO Patent for Anti-CD123 Immunoconjugates Treating AML

This document is a USPTO patent application (US20260083749A1) concerning anti-CD123 immunoconjugates for treating acute myeloid leukemia (AML). The patent claims methods and uses of these immunoconjugates, including pivekimab sunirine, as monotherapies or in combination with BCL-2 inhibitors (e.g., venetoclax) or hypomethylating agents (e.g., azacitidine, decitabine). The stated purpose is to prepare AML patients for hematopoietic stem cell transplant and to achieve complete remissions, particularly in patients with poor prognostic markers.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signifies potential future intellectual property rights and market exclusivity for specific treatments related to AML. Companies involved in the development or commercialization of AML therapies, particularly those utilizing immunoconjugates or combination therapies involving BCL-2 inhibitors or hypomethylating agents, should be aware of this filing for competitive intelligence and potential licensing considerations.